907 related articles for article (PubMed ID: 22080568)
1. Identification of genes upregulated in ALK-positive and EGFR/KRAS/ALK-negative lung adenocarcinomas.
Okayama H; Kohno T; Ishii Y; Shimada Y; Shiraishi K; Iwakawa R; Furuta K; Tsuta K; Shibata T; Yamamoto S; Watanabe S; Sakamoto H; Kumamoto K; Takenoshita S; Gotoh N; Mizuno H; Sarai A; Kawano S; Yamaguchi R; Miyano S; Yokota J
Cancer Res; 2012 Jan; 72(1):100-11. PubMed ID: 22080568
[TBL] [Abstract][Full Text] [Related]
2. EGFR, ERBB2, and KRAS mutations in Korean non-small cell lung cancer patients.
Bae NC; Chae MH; Lee MH; Kim KM; Lee EB; Kim CH; Park TI; Han SB; Jheon S; Jung TH; Park JY
Cancer Genet Cytogenet; 2007 Mar; 173(2):107-13. PubMed ID: 17321325
[TBL] [Abstract][Full Text] [Related]
3. Molecular changes of epidermal growth factor receptor (EGFR) and KRAS and their impact on the clinical outcomes in surgically resected adenocarcinoma of the lung.
Kim YT; Kim TY; Lee DS; Park SJ; Park JY; Seo SJ; Choi HS; Kang HJ; Hahn S; Kang CH; Sung SW; Kim JH
Lung Cancer; 2008 Jan; 59(1):111-8. PubMed ID: 17904685
[TBL] [Abstract][Full Text] [Related]
4. Anaplastic lymphoma kinase immunoreactivity correlates with ALK gene rearrangement and transcriptional up-regulation in non-small cell lung carcinomas.
Boland JM; Erdogan S; Vasmatzis G; Yang P; Tillmans LS; Johnson MR; Wang X; Peterson LM; Halling KC; Oliveira AM; Aubry MC; Yi ES
Hum Pathol; 2009 Aug; 40(8):1152-8. PubMed ID: 19386350
[TBL] [Abstract][Full Text] [Related]
5. Correlation of cytomorphology and molecular findings in EGFR+, KRAS+, and ALK+ lung carcinomas.
Li Z; Dacic S; Pantanowitz L; Khalbuss WE; Nikiforova MN; Monaco SE
Am J Clin Pathol; 2014 Mar; 141(3):420-8. PubMed ID: 24515771
[TBL] [Abstract][Full Text] [Related]
6. Molecular context of the EGFR mutations: evidence for the activation of mTOR/S6K signaling.
Conde E; Angulo B; Tang M; Morente M; Torres-Lanzas J; Lopez-Encuentra A; Lopez-Rios F; Sanchez-Cespedes M
Clin Cancer Res; 2006 Feb; 12(3 Pt 1):710-7. PubMed ID: 16467080
[TBL] [Abstract][Full Text] [Related]
7. Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features.
Tam IY; Chung LP; Suen WS; Wang E; Wong MC; Ho KK; Lam WK; Chiu SW; Girard L; Minna JD; Gazdar AF; Wong MP
Clin Cancer Res; 2006 Mar; 12(5):1647-53. PubMed ID: 16533793
[TBL] [Abstract][Full Text] [Related]
8. Association of p16 homozygous deletions with clinicopathologic characteristics and EGFR/KRAS/p53 mutations in lung adenocarcinoma.
Iwakawa R; Kohno T; Anami Y; Noguchi M; Suzuki K; Matsuno Y; Mishima K; Nishikawa R; Tashiro F; Yokota J
Clin Cancer Res; 2008 Jun; 14(12):3746-53. PubMed ID: 18559592
[TBL] [Abstract][Full Text] [Related]
9. Somatic mutations of the HER2 kinase domain in lung adenocarcinomas.
Shigematsu H; Takahashi T; Nomura M; Majmudar K; Suzuki M; Lee H; Wistuba II; Fong KM; Toyooka S; Shimizu N; Fujisawa T; Minna JD; Gazdar AF
Cancer Res; 2005 Mar; 65(5):1642-6. PubMed ID: 15753357
[TBL] [Abstract][Full Text] [Related]
10. Cytomorphological features of ALK-positive lung adenocarcinomas: psammoma bodies and signet ring cells.
Pareja F; Crapanzano JP; Mansukhani MM; Bulman WA; Saqi A
Cancer Cytopathol; 2015 Mar; 123(3):162-70. PubMed ID: 25557162
[TBL] [Abstract][Full Text] [Related]
11. Distinctive evaluation of nonmucinous and mucinous subtypes of bronchioloalveolar carcinomas in EGFR and K-ras gene-mutation analyses for Japanese lung adenocarcinomas: confirmation of the correlations with histologic subtypes and gene mutations.
Sakuma Y; Matsukuma S; Yoshihara M; Nakamura Y; Noda K; Nakayama H; Kameda Y; Tsuchiya E; Miyagi Y
Am J Clin Pathol; 2007 Jul; 128(1):100-8. PubMed ID: 17580276
[TBL] [Abstract][Full Text] [Related]
12. Frequent ALK rearrangement and TTF-1/p63 co-expression in lung adenocarcinoma with signet-ring cell component.
Yoshida A; Tsuta K; Watanabe S; Sekine I; Fukayama M; Tsuda H; Furuta K; Shibata T
Lung Cancer; 2011 Jun; 72(3):309-15. PubMed ID: 21036415
[TBL] [Abstract][Full Text] [Related]
13. Epidermal growth factor receptor gene mutation defines distinct subsets among small adenocarcinomas of the lung.
Haneda H; Sasaki H; Shimizu S; Endo K; Suzuki E; Yukiue H; Kobayashi Y; Yano M; Fujii Y
Lung Cancer; 2006 Apr; 52(1):47-52. PubMed ID: 16503085
[TBL] [Abstract][Full Text] [Related]
14. Reversed mutation rates of KRAS and EGFR genes in adenocarcinoma of the lung in Taiwan and their implications.
Wu CC; Hsu HY; Liu HP; Chang JW; Chen YT; Hsieh WY; Hsieh JJ; Hsieh MS; Chen YR; Huang SF
Cancer; 2008 Dec; 113(11):3199-208. PubMed ID: 18932251
[TBL] [Abstract][Full Text] [Related]
15. Mucinous differentiation correlates with absence of EGFR mutation and presence of KRAS mutation in lung adenocarcinomas with bronchioloalveolar features.
Finberg KE; Sequist LV; Joshi VA; Muzikansky A; Miller JM; Han M; Beheshti J; Chirieac LR; Mark EJ; Iafrate AJ
J Mol Diagn; 2007 Jul; 9(3):320-6. PubMed ID: 17591931
[TBL] [Abstract][Full Text] [Related]
16. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications.
Kosaka T; Yatabe Y; Endoh H; Kuwano H; Takahashi T; Mitsudomi T
Cancer Res; 2004 Dec; 64(24):8919-23. PubMed ID: 15604253
[TBL] [Abstract][Full Text] [Related]
17. EGFR, KRAS, BRAF and ALK gene alterations in lung adenocarcinomas: patient outcome, interplay with morphology and immunophenotype.
Warth A; Penzel R; Lindenmaier H; Brandt R; Stenzinger A; Herpel E; Goeppert B; Thomas M; Herth FJ; Dienemann H; Schnabel PA; Schirmacher P; Hoffmann H; Muley T; Weichert W
Eur Respir J; 2014 Mar; 43(3):872-83. PubMed ID: 23988776
[TBL] [Abstract][Full Text] [Related]
18. Multiparametric molecular characterization of pulmonary sarcomatoid carcinoma reveals a nonrandom amplification of anaplastic lymphoma kinase (ALK) gene.
Pelosi G; Gasparini P; Cavazza A; Rossi G; Graziano P; Barbareschi M; Perrone F; Barberis M; Takagi M; Kunimura T; Yamada T; Nakatani Y; Pastorino U; Scanagatta P; Sozzi G; Garassino M; De Braud F; Papotti M
Lung Cancer; 2012 Sep; 77(3):507-14. PubMed ID: 22705117
[TBL] [Abstract][Full Text] [Related]
19. Chromosomal imbalances in lung adenocarcinomas with or without mutations in the epidermal growth factor receptor gene.
Fong Y; Lin YS; Liou CP; Li CF; Tzeng CC
Respirology; 2010 May; 15(4):700-5. PubMed ID: 20409020
[TBL] [Abstract][Full Text] [Related]
20. Prognostic and therapeutic implications of EGFR and KRAS mutations in resected lung adenocarcinoma.
Marks JL; Broderick S; Zhou Q; Chitale D; Li AR; Zakowski MF; Kris MG; Rusch VW; Azzoli CG; Seshan VE; Ladanyi M; Pao W
J Thorac Oncol; 2008 Feb; 3(2):111-6. PubMed ID: 18303429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
